First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer

Inclusion Criteria

• •1. Ability to understand and willingness to sign a written informed consent document.
• •2. Age 18 or more years
• •3. Confirmed presence of locally advanced, unresectable or metastatic pancreatic adenocarcinoma (other pancreatic malignant histologies are excluded) with measurable disease per RECIST (version 1.1) (i.e. at least 1 lesion \> 1 cm or lymph node \> 1.5 cm in short axis)
• •4. Participant must have documented tumor progression during or following at least one prior systemic regimen as established by CT or MRI scan within 28 days of enrollment
• •5. Eastern Cooperative Oncology Group Performance Status ≤ 2
• •6. Participant must have completed prior chemotherapy at least 2 weeks (washout period) prior to \[68Ga\]Ga DOTA-5G PET scan. Any clinically significant toxicity (with the exceptions of hair loss and sensory neuropathy) related to prior therapy resolved to Grade 1 or baseline.
• •7. Hematologic parameters defined as:
• •1. Absolute neutrophil count (ANC) ≥ 1000 cells/mm3
• •2. Platelet count ≥ 100,000/mm3
• •3. Hemoglobin ≥ 8 g/dL
• •8. Blood chemistry levels defined as:
• •1. AST, ALT, alkaline phosphatase ≤ 5 times upper limit of normal (ULN)
• •2. Total bilirubin ≤ 2 times ULN
• •3. Creatinine ≤ 2 times ULN
• •9. Anticipated life expectancy ≥ 3 months
• •10. Able to remain motionless for up to 30-60 minutes per scan
• •1. Completion of entry into \[68Ga\]Ga DOTA-5G PET study and completion of scan
• •2. The presence of at least one measurable disease by \[68Ga\]Ga DOTA-5G PET/CT (SUVmax\>2-fold above normal lung or liver)